Citations

Clear

4847 citation(s) found for "Tu, Eric".

Integrated transcriptomic analysis of human induced pluripotent stem cell-derived osteogenic differentiation reveals a regulatory role of KLF16
Ying, Ru , Ma, Meng , Cohen, Ninette, D’Souza, Sunita L. , Schaniel, Christoph , Perrine, Susan M. Motch , Pichurin, Oksana , Holmes, Greg , Schadt, Eric E. , Zhang, Bin , Ru, Ying, Zhou, Xianxiao , Kriti, Divya , Kuo, Sharon , Pinto, Dalila , Housman, Genevieve , Bakel, Harm van , Jabs, Ethylin W , Wu, Meng

Mayo Clinic

No container title available | May 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.106265 Get It

Abstract Osteogenic differentiation is essential for bone development, metabolism, and repair; however, the underlying regulatory relationships among genes remain poorly understood. To elucidate the transcriptomic changes and identify novel regulatory genes involved in osteogenic differentiation, we differentiated mesenchymal stem cells (MSCs) derived from 20 human iPSC lines into preosteoblasts (preOBs) and osteoblasts (OBs). We then performed transcriptome profiling of MSCs, preOBs and OBs. The iPSC-derived MSCs and OBs showed similar transcriptome profiles to those of primary human MSCs and OBs, respectively. Differential gene expression analysis revealed global changes in the transcriptomes from MSCs to preOBs, and then to OBs, including the differential expression of 840 genes encoding transcription factors (TFs). TF regulatory network analysis uncovered a network comprising 451 TFs, organized into five interactive modules. Multiscale embedded gene co-expression network analysis (MEGENA) identified gene co-expression modules and key network regulators (KNRs). From these analyses, KLF16 emerged as an important TF in osteogenic differentiation. We demonstrate that overexpression of Klf16 in vitro inhibited osteogenic differentiation and mineralization, while Klf16+/- mice exhibited increased bone mineral density, trabecular number, and cortical bone area. Our study underscores the complexity of osteogenic differentiation and identifies novel regulatory genes such as KLF16, which plays an inhibitory role in osteogenic differentiation both in vitro and in vivo.
Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
Petersen, Ronald C. , Graf, Ana, Atkins, Alexandra S. , Murphy, Jennifer, Miller, David S. , Reyderman, Larisa, Siemers, Eric , Smith, Janice , Carrillo, María C. , Weber, Christopher J., Bryś, Mirosław , Murphy, Jennifer

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | May 24, 2025 | Volume: 11 | Issue: 2 | Pages: No page available

10.1002/trc2.70069 | PMID 40417267 Get It

Abstract The Alzheimer's disease (AD) scientific field continues to make significant advances in early detection and treatments, which importantly rest on advances in our fundamental understanding of AD pathobiology and its contribution to cognitive decline. Clinical readouts of monoclonal antibodies against various forms of the amyloid beta (Aβ) protein indicate that the impact of these treatments may extend beyond reduction in amyloid plaques. The Alzheimer's Association Research Roundtable meeting held on May 17 and 18, 2022, reviewed our understanding to date of the impact of treatments targeting various species of Aβ; its impact on other related pathophysiology including tau; and ultimately, its effects on neurodegeneration and clinical decline, driven by the latest available data. Participants discussed the current evidence for a causal relationship among amyloid accumulation, tau alteration, and cognitive decline; the effect of anti‐amyloid therapies on clinical and biomarker endpoints; and how we can accelerate the pathway to therapeutic approval and what should guide us for the near future. Highlights The Alzheimer's Association Research Roundtable convened leaders from industry and academia, as well as patients, clinicians, and government and regulatory agency scientists to discuss the topic “Current Understanding of AD Pathophysiology & Impact of Amyloid‐beta Targeted Treatments on Biomarkers and Clinical Endpoints.” The totality of scientific evidence (clinical trials, animal data, modeling, and observational studies) on the relationship between amyloid beta (Aβ), amyloid, tau, and cognitive impairment is helping our understanding of the downstream effects and overall importance of lowering amyloid plaque load. Based on data from multiple phase 2 and 3 clinical trials of anti‐amyloid monoclonal antibodies, there is strong evidence to support that a sufficiently large reduction in amyloid plaque load to near‐normal levels is associated with positive changes in tau biomarkers and clinical endpoints. Reduction of Aβ plaque, measured easily by plasma amyloid biomarkers, is reasonably likely to predict benefit in clinical outcome measures.
Ubiquitin–proteasome system in the different stages of dominantly inherited Alzheimer's disease
Hassenstab, Jason , Sung, Yun Ju, Daniels, Alisha , Xiong, Chengjie , Perrin, Richard J. , Day, Gregory S. , Supnet, Charlene , Berman, Sarah , Chhatwal, Jasmeer P. , Huey, Edward D. , Ryan, Natalie S. , Laske, Christoph , Xiong, Chengjie , Roh, Jee Hoon , Lopera, Francisco , team, For DIAN study, McDade, Eric M , Day, Gregory S , Xiong, Chengjie , Hassenstab, Jason , Roh, Jee Hoon , Supnet-Bell, Charlene , Berman, Sarah , Liu, Haiyan , Bui, Quoc Van Phu , Gordon, Brian A. , Benzinger, Tammie L.S. , Timsina, Jigyasha , Sung, Yun Ju, Karch, Celeste M. , Renton, Alan , Morris, John C. , Ibanez, Laura , Llibre‐Guerra, Jorge J. , Xu, Xiong, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Brooks, William S. , Jucker, Mathias , Vöglein, Jonathan , Lopera, Francisco Javier , Bateman, Randall J. , Cruchaga, Carlos , McDade, Eric , team, For DIAN study

Mayo Clinic

Alzheimer's & Dementia | May 24, 2025 | Volume: 21 | Issue: 5 | Pages: No page available

10.1002/alz.70243 | PMID 40411302 Get It

AbstractINTRODUCTIONThis study investigated the role of the ubiquitin–proteasome system (UPS) in dominantly inherited Alzheimer's disease (DIAD) by examining cerebrospinal fluid (CSF) levels of UPS proteins.METHODThe SOMAscan assay was used to detect changes in UPS proteins in mutation carriers (MCs) relative to disease progression; imaging and CSF biomarkers of amyloid, tau, and neurodegeneration measures; and Clinical Dementia Rating scale.RESULTSSubtle increases in specific ubiquitin enzymes were detected in MCs up to two decades before symptom onset, with more pronounced elevations in UPS‐activating enzymes near symptom onset. Significant correlations were found between UPS proteins and Alzheimer's disease (AD) biomarkers, especially between autophagy markers and late‐stage tau biomarkers, microglia, and axonal degeneration.DISCUSSIONThe rise in UPS proteins alongside tau‐related markers suggests UPS involvement in tau neurofibrillary tangles. Elevated CSF UPS proteins in DIAD MCs may serve as indicators of disease progression, and may support the UPS as a therapeutic target in AD.Highlights This study investigates the ubiquitin‐proteasome system (UPS) in Dominantly Inherited Alzheimer's Disease (DIAD), highlighting early molecular changes linked to disease progression. Using SOMAscan proteomics, we identified significant UPS protein alterations in cerebrospinal fluid of mutation carriers, notably up to 20 years before clinical symptom onset. Correlations between UPS protein levels and Alzheimer's biomarkers, particularly tau and neurodegeneration markers, suggest a strong association between UPS dysregulation and tau pathology in DIAD. Dynamic UPS changes align with A/T biological staging: UPS proteins were shown to increase across Aβ/tau (A/T) groups, with largest increases in the A+/T+ group, reinforcing their role in late‐stage tau pathology and disease progression. These findings underscore the potential of UPS proteins as early biomarkers for Alzheimer's disease progression and as novel therapeutic targets, especially in tau‐pathology‐driven neurodegeneration. This work contributes to understanding AD pathogenesis, by emphasizing the importance of protein quality control systems and by offering avenues for future biomarker discovery and therapeutic development in Alzheimer's disease.
A comparative study on the effect of age on Neck Disability Index improvement at 24 months after surgical intervention for cervical spondylotic myelopathy: a Quality Outcomes Database study
Sherrod, Brandon A. , Rosero, Spencer , Chan, Andrew K. , Shaffrey, Christopher I., Gottfried, Oren N., Bydon, Mohamad , Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Fu, Kai-Ming, Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Shaffrey, Mark E., Tumialán, Luis M. , Turner, Jay D. , Chou, Dean , Haid, Regis W., Mummaneni, Praveen V., Bisson, Erica F. , Porche, Ken M. , Shaffrey, Christopher I. , Fu, Kai-Ming, Uribe, Juan S. , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | May 23, 2025 | Volume: 43 | Issue: 2 | Pages: 154-169

10.3171/2025.3.spine24598 | PMID 40408883 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) is often accompanied by neck pain, which, along with more recognized neurological deficits like motor and sensory changes, significantly impacts patients’ quality of life. The authors examined whether age influences improvements in neck disability and related quality-of-life measures after surgery for CSM. Using the Neck Disability Index (NDI) as the primary outcome, they compared long-term outcomes at 24 months among patients aged ≥ 65, ≥75, and < 65 years, exploring the effects of surgical intervention on both pain-related disability and functional recovery in older adults. METHODS Using the Quality Outcomes Database, the authors conducted a detailed propensity score–matched analysis on cohorts aged ≥ 65 and ≥ 75 years compared with a < 65-year-old cohort while controlling for baseline NDI scores, other demographic variables, health status, underlying pathology, number of levels, indication for surgery, surgical approach, and type of surgery. Differences in NDI total and subdomain scores at 24 months postoperatively were the primary measures of improvement. Age-related variability in NDI differential was assessed. EQ-5D and calculated SF-6D were secondary measures. RESULTS Of the 1141 patients in the cohort (January 2016 to December 2018), 687 patients were < 65 years, 325 were 65 to < 75 years, and 129 were ≥ 75 years of age. After propensity score matching, 197 patients each were well matched in the ≥ 65-year (mean 71.4 years) and < 65-year (mean 55.3 years) cohorts; similarly, 57 patients each were matched in the ≥ 75-year (mean 78.3 years) and < 65-year (mean 55.8 years) cohorts. Improvements in NDI scores and subdomain scores, EQ-5D, and calculated SF-6D were consistent at 3, 12, and 24 months postoperatively across all cohorts. At 24 months, patients ≥ 65 years showed NDI score improvements (−14.7 ± 22.3) similar to those < 65 years (−13.0 ± 21.3, p = 0.454), and patients ≥ 75 years demonstrated NDI improvements (−15.0 ± 19.7) comparable to those < 65 years (−17.6 ± 20.4, p = 0.499). A sensitivity analysis for linear relationship found that NDI improvement was statistically greater in older patients (7.5 points every 30 years, p < 0.0001), but this difference was below the minimal clinically important difference. Other clinical outcomes were similar between cohorts. CONCLUSIONS Surgical intervention for CSM yields substantial and similar improvements in NDI scores and other metrics among various age groups, including those aged at least 65 and 75 years. These results highlight the effectiveness of surgery across a broad patient demographic, underscoring its value in treating CSM irrespective of age.
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma
Abel, Kathryn M. Van , Price, Katharine A., Moore, Eric J. , Patel, Samir H. , Hinni, Michael L., Fruth, Briant, Foster, Nathan R. , Neben-Wittich, M.A. , Garces, Yolanda I. , McGee, L.A. , Gamez, Mauricio E. , Rwigema, Jean‐Claude M. , Janus, Jeffrey R. , Kasperbauer, Jan L. , García, Joaquín J., Foote, Robert L. , Daniel, Jeannie, Neben-Wittich, Michelle, McGee, Lisa A, Lester, Scott C. , Holtzman, Adam L. , Van Abel, Kathryn M , Routman, David M. , Yin, Linda X. , Price, Daniel L. , Chintakuntlawar, Ashish V. , Ma, Daniel J.

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | May 22, 2025 | Volume: 151 | Issue: 7 | Pages: 665

10.1001/jamaoto.2025.0903 | PMID 40402484 Get It

ImportanceThe De-escalated Adjuvant Radiation Therapy (DART) phase 3 randomized clinical trial (RCT) showed that in patients with human papillomavirus (HPV)−associated oropharyngeal squamous cell carcinoma, postoperative minimal residual disease (MRD), detected through circulating tumor HPV DNA (ctHPVDNA), was associated with a higher risk of disease progression. When considered along with pathologic factors, postoperative ctHPVDNA assessment may improve patient selection for adjuvant treatment de-escalation; however, more data are needed to demonstrate how it may be used in personalizing treatment intensity.ObjectiveTo determine the association of postoperative MRD status with progression-free survival (PFS) after surgery for HPV-associated oropharyngeal squamous cell carcinoma.Design, Setting, and ParticipantsThis was a secondary analysis of the DART RCT, which was conducted from October 2016 to August 2020 in multiple sites in the US. Participants from the de-escalated adjuvant radiation therapy group and the standard of care group with available blood specimen data were included. Reports from 3-month posttreatment surveillance visits were used to assess associations and outcomes. Data analyses were performed from March 2023 to March of 2025.InterventionsThe DART group received 30 to 36 Gy of radiation therapy in 1.5 to 1.8 Gy twice daily, plus docetaxel, 15 mg/m2, on days 1 and 8. The standard of care group received 60 Gy with or without weekly cisplatin, 40 mg/m2.Main Outcome and MeasurePFS.ResultsThe analysis included 140 patients (mean [SD] age, 59.1 [8.4] years; 12 [8.6%] females and 128 [91.4%] males; 97 [69.3%] with no smoking history); characteristics were similar to the overall DART RCT population. Of these, 17 patients (12.1%) had postoperative MRD (13 of 96 [13.5%] receiving DART and 4 of 44 [9.1%] receiving standard of care). For all patients, postoperative MRD positivity was strongly associated with worsened PFS at 24 months (MRD positivity, 69.5%; MRD negativity, 95.9%; hazard ratio [HR], 0.19; 95% CI, 0.06-0.59). MRD positivity was associated with PFS when evaluating only those patients in the DART group, where 24-month PFS was 68.4% compared to 92.6% for MRD-negative patients (HR, 0.28; 95% CI, 0.08-0.93). Three months after completion of all treatment, 8 of 117 patients (6.8%) had detectable ctHPVDNA, whereas 109 of 117 (93.2%) did not, and detection was highly associated with PFS (HR, 20.48; 95% CI, 6.91-60.67).Conclusions and RelevanceThis secondary analysis of the DART RCT found that patients with detectable ctHPVDNA after surgery had a higher risk of disease progression. When added to the pathologic factors considered, ctHPVDNA assessment may improve selection of patients for treatment de-escalation. In addition, the 3-month posttreatment time point, early in surveillance, may identify a sizable portion of patients with progression and may guide intervention and surveillance after surgery for HPV-associated oropharyngeal squamous cell carcinoma.Trial RegistrationClinicalTrials.gov Identifier: NCT02908477
Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Rosen, Darin , Kolb, Todd M. , Mathai, Stephen C. , Suresh, Karthik , D’Amico, Rachel, Hsu, Steven , Tedford, Ryan J. , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Farha, Samar , Grünig, Gabriele , Jellis, Christine , Kwon, Deborah , Park, Margaret , Xiao, L, Fessel, Jeffrey , Fu, Yongping , Postow, Lisa, Schmetter, Barry, Sutliff, R, Tian, Xuefei , Joseloff, Elizabeth, Wong, Brenda , Lawler, Laurie, Maron, B, Haythe, Jennifer , Krishnan, Udhay , Payne, David A., Bergman, Geoffrey , Bastert, K, Devereux, Richard B. , Kim, Ju Youn , Lohman, Julia, Racanelli, Alexandra C. , Ricketts, Michelle L., Sobol, Irina , Singh, Harsimran , Weinsaft, Jonathan W. , Mathai, S.C. , Carey, Kyle A. , Damico, Rachel L. , Enobun, Blessing , Sanni, Y, Brock, Heinz, Durst, Louise A., Head, Denise , Foley, Thomas A. , Gochanour, Benjamin R. , Halbach, H, Krowka, Michael J. , Menon, David K. , Park, Gyu Tae , Redfield, Margaret M. , Rohwer, Kristi, Williamson, Eric E. , Vanderpool, R, Yuan, Jason X.‐J. , Lim, C.S., Abidov, Aiden , Erickson, Harold , Cunningham, James M. , Pugh, Meredith E., Robbins, Ivan M. , Beck, Gerald J. , Aldred, Micheala A. , Asosingh, Kewal, Aylor, Joan, Beck, B, Borowski, A, Collart, Clara, Comhair, S.A.A., Drinko, Jeanne K., Finet, J. Emanuel , Flinn, Aisling M. , Geraci, M, Jacob, Miriam , Kanta, Alexandra, Larive, Brett , Lempel, Jason K. , Li, Minghui , MacKrell, J., Neumann, D., Nawabit, R, Odabashian, Jill, Olman, Mitchell A. , Park, M, Radeva, Milena , Renapurkar, R, Sharp, Jacqueline, Sherer, Stefan, WHW, Tang, Thomas, Jason , Wadih, K, Wells, Simon P. , Wilcox, Jane, Yu, S, Rounds, Sharon , Bull, Todd , Cadigan, John B., Rosen, Darin T , Rosenzweig, Erika B , Rischard, Franz P , Frantz, Robert P , Beck, Gerald J , Hill, Nicholas S , Barnard, John , Grunig, Gabriele , Jellis, Christine L , Kwon, Deborah H , Mehra, Reena , Park, Margaret M , Tang, W H Wilson , Hassoun, Paul M , Simpson, Catherine E , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Tedford, Ryan J , Mathai, Stephen C , Hsu, Steven , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Barnard, John , Mehra, Reena , Tang, W.H. Wilson , Hassoun, Paul M. , Simpson, Catherine E. , Xiao, L, Fu, Y‐P, Gray, Michael P. , Wong, B, Waxman, Aaron B. , Systrom, David M , Brady, David J. , Chung, Wendy K. , Payne, D, Karas, Maria , Lohman, J, Ricketts, M, Balasubramanian, A, Carey, K, Gao, Lei , Halushka, Marc K. , Kass, David A. , Lin, Ting‐Tse , Mukherjee, Monica , Roth, J, Sanni, Y, Weiss, Robert E. , Zimmerman, Stefan L , Behfar, Atta , Borlaug, Barry A. , Brock, H Du, Head, D, Kane, Garvan C. , Sands, T. , Scott, Christopher G. , Terzic, André , Williamson, E, Garcia, Joe G. N. , Lim, C, Desai, Akshay S , Hansen, L, Newman, J, Brittain, Evan L , Cheng, Feixiong , Filippo, F Di, Flinn, A, Hu, Bo , Jaber, Wael A. , Kanta, A, Martín, Maite Velázquez , McCarthy, Kevin , Ramos, J, Wiggins, K, Willard, Belinda B. , Benza, Raymond L. , Fang, James C. , Gomberg‐Maitland, Mardi

Mayo Clinic

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597 Get It

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
Characterizing Disease Severity Through Surgical Recurrence Rates in Idiopathic Subglottic Stenosis
Bowen, Andrew J. , Awadallah, Andrew S. , McCalla, Monet, Roitman, Ariel , Ali, Hawa M. , Leverson, Glen, Khalil, Yousuf H. , Ring, Sydney , Edell, Eric S. , Xie, Katherine , Francis, David O. , Ekbom, Dale C. , Dailey, Seth H. , Bowen, Andrew Jay , Awadallah, Andrew , Ali, Hawa , Edell, Eric, Koster, Matthew, Xie, Katherine Z , Davis, Ruth , Francis, David O , Ekbom, Dale , Dailey, Seth H , Koster, Matthew J. , Bayan, Semirra L.

Mayo Clinic

The Laryngoscope | May 21, 2025 | Volume: 135 | Issue: 10 | Pages: 3766-3773

10.1002/lary.32280 | PMID 40396584 Get It

ABSTRACTObjectiveThere is currently not a marker of disease severity in idiopathic subglottic stenosis (iSGS). Our objective was to characterize iSGS patients' disease severity using endoscopic surgery rates.MethodsThis was a two‐center retrospective analysis of iSGS patients with a minimum of 4 years of follow up following an initial endoscopic procedure (laser wedge excision (LWE) or endoscopic dilation (ED)). Disease severity was classified into Groups A–C, based on whether patients had fewer (Group A), the same number (Group B), or more surgeries (Group C) in years 3–5 compared to years 1 and 2. Disease severity proportions were compared across institutions using chi‐square analysis. Nonparametric testing compared clinical characteristics such as age, BMI, and GERD across severity groups.ResultsThere were 104 patients from institution 1 and 53 patients from institution 2 that were all female and predominantly Caucasian. Both institutions had clinically and statistically similar proportions of patients in Group A (64% vs. 62%), Group B (20% vs. 19%), and Group C (16% vs. 19%) disease (p > 0.05). No clinical characteristic (e.g., age, sex, race, BMI, GERD) was associated with disease severity.ConclusionAcross tertiary care institutions there is a consistent proportion of iSGS patients who either demonstrate nonrecurrent/decelerating (Group A), stable but persistent (Group B), or rapidly recurring disease (Group C). Two‐year surgery rates appear to be an important timepoint for providing expectations to patients on the likelihood of possessing severe disease.Level of Evidence4
Trends in the Extent of Surgical Management for Low‐Grade Parotid Malignancies: A SEER Analysis
Rourk, Katelyn S. , Ali, Hawa M. , Glasgow, Amy E. , Tasche, Kendall K. , Abel, Kathryn M. Van , Moore, Eric J. , Calcano, Gabriela A. , Yin, Linda X , Van Abel, Kathryn M , Rourk, Katelyn , Habermann, Elizabeth B. , Price, Daniel L. , Yin, Linda X.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | May 21, 2025 | Volume: 173 | Issue: 3 | Pages: 671-680

10.1002/ohn.1305 | PMID 40396455 Get It

AbstractObjectiveLow‐grade parotid malignancies have high overall survival rates; however, controversy remains about the appropriate extent of surgery. We aim to explore the trends in the extent of parotidectomy performed over time in low‐grade parotid malignancies in the United States, with a hypothesis that there has been a trend towards less aggressive surgery.Study DesignRetrospective cohort study of all low‐grade (grade I) acinic cell carcinoma (ACC) and mucoepidermoid carcinoma (MEC) in the Surveillance, Epidemiology, and End Results (SEER) from 2004 to 2020.SettingGeographic areas served by SEER.MethodsTrends were assessed using Cochran‐Armitage tests and logistic regression; Kaplan‐Meier survival curves were used to analyze overall and cancer‐specific survival, and chi‐square tests were used to analyze patient characteristics.ResultsIn total, 1288 patients were identified (916 MEC; 372 ACC). Most patients (n = 772, 60%) were non‐Hispanic white, with an average age of 50.6 years and had a slight female predominance (1.58:1). Most of the cohort presented with tumor stage T1 or T2 (84%), N0 (90.1%), and M0 (96.9%). Treatment with total parotidectomy decreased significantly (34.6 vs 17.7%, P = .02) whereas sacrificing the facial nerve (FN) slightly decreased (20 vs 15.7%, P = .1). A significant increase in N0 patients (71%‐94%, P < .0001) was observed, whereas T staging remained stable (61%‐64%, P = .3). Overall, both ACC and MEC had excellent cancer‐specific survival.ConclusionOver the last 17 years, there has been a significant de‐escalation in the extent of parotidectomy for low‐grade parotid malignancy in the United States.
Are There Differences in 2-Year Outcomes Between Two-Level Anterior Cervical Diskectomy and Fusion Versus Single-Level Anterior Cervical Corpectomy and Fusion to Treat Cervical Myelopathy? A Quality Outcomes Database Study
Berlin, Connor , Mummaneni, Praveen V., Chan, Andrew K. , Chou, Dean , Fu, Kai-Ming, Bydon, Mohamad , Bisson, Erica F. , Shaffrey, Christopher I. , Gottfried, Oren N., Asher, Anthony L. , Coric, Domagoj , Potts, Eric A. , Foley, Kevin T. , Wang, Michael Y. , Virk, Michael S. , Knightly, John J. , Meyer, Scott A., Upadhyaya, Cheerag D., Tumialán, Luis M. , Turner, Jay D. , Uribe, Juan S. , Haid, Regis W., Yen, Chun-Po , Shaffrey, Mark E., Shaffrey, Mark E , Ibrahim, Sufyan , Mummaneni, Praveen V. , Park, Paul

Mayo Clinic

Neurosurgery | May 19, 2025 | Volume: 97 | Issue: 5 | Pages: 1091-1099

10.1227/neu.0000000000003518 | PMID 40388528 Get It

BACKGROUND AND OBJECTIVES: There has been limited assessment between anterior cervical diskectomy and fusion (ACDF) and anterior cervical corpectomy and fusion (ACCF) on patient-reported outcome measures (PROMs) in the treatment of cervical spondylotic myelopathy. We sought to compare PROMs from two-level ACDF with single-level ACCF procedures. We evaluate these results in the context of minimum clinically important difference (MCID) thresholds, which have not been performed previously. METHODS: This retrospective analysis of prospectively collected data from the Quality Outcomes Database Spine Collaborative Research Study Group compared two-level ACDF and single-level ACCF at 3-, 12-, and 24 months postoperatively. PROMs included arm pain Numeric Rating Scale, neck pain Numeric Rating Scale, Neck Disability Index, and North American Spine Society Patient Satisfaction Index. Multivariate logistic regression was used to determine differences in perioperative outcomes, as well as the impact of two-level ACDF vs one-level ACCF on PROMs. MCID thresholds were based off previously established limits. RESULTS: Three hundred and thirty patients were included (236 ACDF, 94 ACCF), and the follow-up rate was 82% at 2 years. There was a significantly higher baseline age, American Society of Anesthesiologists grade, proportion of diabetes, osteoarthritis, ambulation dependence, and myelopathy severity in the ACCF cohort. On multivariable analysis, the ACCF group had greater average length of stay and estimated blood loss. There were no significant differences between reoperation rates or nonroutine discharge. There were similar rates of MCID achievement for PROMs at all time points. CONCLUSION: This study suggests that both ACDF and ACCF procedures for cervical spondylotic myelopathy are able to achieve similar, clinically meaningful improvements in PROMs by 2 years. Patients undergoing single-level ACCF have more estimated blood loss and longer length of stay, as well as worse baseline myelopathy. Both procedures have efficacious, durable outcomes. It is reasonable that other factors, such as radiographic characteristics and patient symptoms, may influence patient selection for ACDF vs ACCF.
Associations between measures of oestrogen exposure and severity of Fuchs endothelial corneal dystrophy
Petrela, Redion B. , Chhetri, Chandra Divyash, Najafi, Ahmad , Zhang, Zhaoqi, Rinkoski, Tommy A. , Wieben, Eric D. , Fautsch, Michael P. , Patel, Sangita P. , A Rinkoski, Tommy, Patel, Sangita P , Chhetri, Chandra Divyash, Chakraborty, Saptarshi , Millen, Amy E.

Mayo Clinic

BMJ Open Ophthalmology | May 15, 2025 | Volume: 10 | Issue: 1 | Pages: e001884

10.1136/bmjophth-2024-001884 | PMID 40374208 Get It

Aims To determine the associations between measures of oestrogen exposure and Fuchs endothelial corneal dystrophy (FECD) severity. Methods Clinic-based cross-sectional study of 32 postmenopausal women and 11 men with mild or severe FECD, age>55 years. Participants completed questionnaires for data on demographics, anthropometric factors, medical history and potential risk factors for FECD. Women completed an additional reproductive history questionnaire used to calculate the months of lifetime oestrogen exposure. Slit-lamp biomicroscopy, specular microscopy, corneal Scheimpflug tomography and laboratory testing ( TCF4 repeat expansion quantification, total estradiol, free estradiol, sex hormone binding globulin (SHBG), calcaneal bone density) were performed. Logistic regression models were developed to predict FECD severity based on three-way interactions of each oestrogen exposure measure, sex and TCF4 genotype. Results 43 patients were enrolled in the study (mild FECD: 17 women, 3 men; severe FECD: 15 women, 8 men). Serum-free estradiol was higher in the severe compared with mild FECD group (0.21±0.2 vs 0.09±0.1 pg/mL; p=0.046). When stratified by sex, men showed no significant associations between oestrogen measures and FECD severity. However, in women, the odds of severe FECD were increased with more months of lifetime oestrogen exposure (all women; log OR (95% credible interval): 1.3 (0.14 to 4.3)), higher concentrations of free estradiol (all women; 2.1 (0.0049 to 10)), greater % free estradiol (only women without TCF4 repeat expansion; 1.3 (0.16 to 3.8)) and higher concentrations of SHBG (only women with TCF4 repeat expansion; 2.2 (0.45 to 9.1)). Conclusions While the application of these data is constrained by the limited number of participants, a clinic-based sample, small number of men compared with women and single-point measures of serum hormone measures, these data suggest that FECD severity is associated with higher oestrogen exposures in women but not men and may be dependent on TCF4 repeat expansion status.